Intuit to Announce First-Quarter Fiscal Year 2025 Results on Nov. 21

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Intuit Inc. (Nasdaq: INTU), the global financial technology platform that makes TurboTax, Credit Karma, QuickBooks, and Mailchimp, will announce its first-quarter financial results for fiscal year 2025 on November 21, following the close of market. The company’s first quarter ends today.

Intuit executives will discuss the financial results on a conference call at 1:30 p.m. Pacific time on November 21. The conference call can be heard live at https://investors.intuit.com/news-events. Prepared remarks for the call will be available on Intuit’s website after the call ends.

Replay Information

A replay of the conference call will be available for one week by calling 800-839-4198 or 402-220-2988 from international locations. There is no passcode required. The audio call will remain available on Intuit’s website for one week after the conference call.

About Intuit

Intuit is the global financial technology platform that powers prosperity for the people and communities we serve. With approximately 100 million customers worldwide using products such as TurboTax, Credit Karma, QuickBooks, and Mailchimp, we believe that everyone should have the opportunity to prosper. We never stop working to find new, innovative ways to make that possible. Please visit us at Intuit.com and find us on social for the latest information about Intuit and our products and service

View source version on businesswire.com: https://www.businesswire.com/news/home/20241031840650/en/

Investors
Lisa Patterson
Intuit Inc.
650-944-2713
[email protected]

Media
Kali Fry
Intuit Inc.
650-944-3036
[email protected]

Source: Intuit Inc.

You May Also Be Interested In

• SailPoint Technologies Holdings (SAIL) PT Raised to $25 by Cantor Fitzgerald on Solid Checks
• Fortress Appoints Yuko Umino as Head of Private Wealth Solutions for Japan and Harry Bush as Head of Private Wealth Solutions for EMEA
• Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provi